Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, discusses the antibody-drug conjugate T-DM1 that is being investigated as a treatment for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer.
For more information on breast cancer treatments, visit [ Ссылка ]
![](https://s2.save4k.ru/pic/ifitFtlw5lg/mqdefault.jpg)